TrialRMD open2022

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.

Roy Fleischmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.